These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 20493783)
1. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Gonzalez-Heydrich J; Whitney J; Waber D; Forbes P; Hsin O; Faraone SV; Dodds A; Rao S; Mrakotsky C; Macmillan C; Demaso DR; de Moor C; Torres A; Bourgeois B; Biederman J Epilepsy Behav; 2010 Jul; 18(3):229-37. PubMed ID: 20493783 [TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. Wigal SB; Gupta S; Heverin E; Starr HL J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428 [TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440 [TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066 [TBL] [Abstract][Full Text] [Related]
6. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study. Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533 [TBL] [Abstract][Full Text] [Related]
7. Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy. Park J; Choi HW; Yum MS; Ko TS; Shon SH; Kim HW J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):537-546. PubMed ID: 30089215 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065 [TBL] [Abstract][Full Text] [Related]
11. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837 [TBL] [Abstract][Full Text] [Related]
12. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Baptista-Neto L; Dodds A; Rao S; Whitney J; Torres A; Gonzalez-Heydrich J Expert Opin Investig Drugs; 2008 Jan; 17(1):77-84. PubMed ID: 18095920 [TBL] [Abstract][Full Text] [Related]
13. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962 [TBL] [Abstract][Full Text] [Related]
14. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up. Su Y; Yang L; Stein MA; Cao Q; Wang Y J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845 [TBL] [Abstract][Full Text] [Related]
15. Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate? Socanski D; Aurlien D; Herigstad A; Thomsen PH; Larsen TK Seizure; 2015 Feb; 25():80-3. PubMed ID: 25645642 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting. Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795 [TBL] [Abstract][Full Text] [Related]
17. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD. Robison RJ; Reimherr FW; Gale PD; Marchant BK; Williams ED; Soni P; Halls C; Strong RE Ann Clin Psychiatry; 2010 May; 22(2):94-102. PubMed ID: 20445836 [TBL] [Abstract][Full Text] [Related]
18. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. Palumbo D; Spencer T; Lynch J; Co-Chien H; Faraone SV J Child Adolesc Psychopharmacol; 2004; 14(2):185-94. PubMed ID: 15319016 [TBL] [Abstract][Full Text] [Related]
19. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084 [TBL] [Abstract][Full Text] [Related]
20. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Fosi T; Lax-Pericall MT; Scott RC; Neville BG; Aylett SE Epilepsia; 2013 Dec; 54(12):2071-81. PubMed ID: 24304474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]